WO1997019180A2 - Vecteur constitue d'une sequence d'adn de regulation de transcription liee a une sequence d'adn codant pour une beta-lactamase pour therapie a base d'un promedicament enzymatique - Google Patents
Vecteur constitue d'une sequence d'adn de regulation de transcription liee a une sequence d'adn codant pour une beta-lactamase pour therapie a base d'un promedicament enzymatique Download PDFInfo
- Publication number
- WO1997019180A2 WO1997019180A2 PCT/GB1996/002845 GB9602845W WO9719180A2 WO 1997019180 A2 WO1997019180 A2 WO 1997019180A2 GB 9602845 W GB9602845 W GB 9602845W WO 9719180 A2 WO9719180 A2 WO 9719180A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecular
- lactamase
- sequence
- targetted
- chimeara
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57572—Gastrin releasing peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU75839/96A AU7583996A (en) | 1995-11-20 | 1996-11-19 | Vector consisting of a transcriptional regulatory dna sequence linked to a dna sequence encoding beta-lactamase for enzyme prodrug therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523703.8A GB9523703D0 (en) | 1995-11-20 | 1995-11-20 | Enzyme prodrug thearapy |
GB9523703.8 | 1995-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997019180A2 true WO1997019180A2 (fr) | 1997-05-29 |
WO1997019180A3 WO1997019180A3 (fr) | 1997-08-28 |
Family
ID=10784158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002846 WO1997019183A2 (fr) | 1995-11-20 | 1996-11-19 | Transcription specifique pour le tissu d'une sequence d'adn codant une enzyme heterologue connue pour etre utilisee dans une therapie a base d'un promedicament enzymatique pour traiter le cancer du poumon |
PCT/GB1996/002845 WO1997019180A2 (fr) | 1995-11-20 | 1996-11-19 | Vecteur constitue d'une sequence d'adn de regulation de transcription liee a une sequence d'adn codant pour une beta-lactamase pour therapie a base d'un promedicament enzymatique |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002846 WO1997019183A2 (fr) | 1995-11-20 | 1996-11-19 | Transcription specifique pour le tissu d'une sequence d'adn codant une enzyme heterologue connue pour etre utilisee dans une therapie a base d'un promedicament enzymatique pour traiter le cancer du poumon |
Country Status (3)
Country | Link |
---|---|
AU (2) | AU7583996A (fr) |
GB (1) | GB9523703D0 (fr) |
WO (2) | WO1997019183A2 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928888A (en) * | 1996-09-26 | 1999-07-27 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities |
WO1999039741A2 (fr) | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Administration systemique de particules lipidiques du plasmide stables dans le serum en cancerotherapie |
US5955604A (en) * | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
WO1999050406A2 (fr) * | 1998-04-01 | 1999-10-07 | Metamorphix, Inc. | Sequences regulatrices du facteur 9 de differenciation de croissance et utilisations associees |
WO2000020608A1 (fr) * | 1998-10-02 | 2000-04-13 | Genotherapeutics, Inc. | Procede de traitement du cancer de la prostate au moyen d'un vecteur d'expression adenoviral codant pour une enzyme de promedicament |
WO2000066752A2 (fr) * | 1999-05-01 | 2000-11-09 | Astrazeneca Ab | Composes chimiques |
US6291162B1 (en) * | 1995-03-20 | 2001-09-18 | The Regents Of The University Of California | Cytosolic forms of beta-lactamase and uses thereof |
US6339070B1 (en) | 1997-05-10 | 2002-01-15 | Zeneca Limited | Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
US7227013B1 (en) | 1999-03-31 | 2007-06-05 | Metamorphix, Inc. | Growth differentiation factor-9 regulatory sequences and uses therefor |
EP2118304A1 (fr) * | 2007-02-05 | 2009-11-18 | Panbio Limited | Dosages fec homogene in vitro et composants |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0400443D0 (en) | 2004-01-09 | 2004-02-11 | Oxford Biomedica Ltd | Cascade |
US7148035B1 (en) | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
GB0203420D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
GB0203419D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0415731A2 (fr) * | 1989-08-30 | 1991-03-06 | The Wellcome Foundation Limited | Substances nouvelles pour la thérapie du cancer |
WO1996016179A1 (fr) * | 1994-11-18 | 1996-05-30 | The Wellcome Foundation Limited | Therapie genique enzymatique catalysant la conversion extracellulaire d'un precurseur |
-
1995
- 1995-11-20 GB GBGB9523703.8A patent/GB9523703D0/en active Pending
-
1996
- 1996-11-19 AU AU75839/96A patent/AU7583996A/en not_active Abandoned
- 1996-11-19 AU AU77004/96A patent/AU7700496A/en not_active Abandoned
- 1996-11-19 WO PCT/GB1996/002846 patent/WO1997019183A2/fr active Application Filing
- 1996-11-19 WO PCT/GB1996/002845 patent/WO1997019180A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0415731A2 (fr) * | 1989-08-30 | 1991-03-06 | The Wellcome Foundation Limited | Substances nouvelles pour la thérapie du cancer |
WO1996016179A1 (fr) * | 1994-11-18 | 1996-05-30 | The Wellcome Foundation Limited | Therapie genique enzymatique catalysant la conversion extracellulaire d'un precurseur |
Non-Patent Citations (5)
Title |
---|
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 716, May 1994, pages 104-114, XP000654773 HUBER, B.E. ET AL.: "Virus-directed enzyme/prodrug therapy (VDEPT)" * |
CANCER RESEARCH, vol. 53, no. 17, 1 September 1993, pages 3956-3963, XP000561816 MEYER, D.L. ET AL.: "Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models" * |
CANCER RESEARCH, vol. 54, no. 10, 15 May 1994, pages 2719-2723, XP000655095 WALLACE, P.M. ET AL.: "Intratumoral generation of 5-fluorouracil mediated by an antibody cytosine deaminase conjugate in combination with 5-fluorocytosine" * |
GENE THERAPY, vol. 1, no. 3, May 1994, pages 170-175, XP000654731 HARRIS, J.D. ET AL.: "Gene therapy for cancer using tumour-specific prodrug activation" * |
MOLECULAR IMMUNOLOGY, vol. 31, no. 4, March 1994, pages 261-267, XP000654846 DE SUTTER, K. AND FIERST WALTER: "A bifunctional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase" * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071761B2 (en) | 1995-03-20 | 2011-12-06 | The Regents Of The University Of California | Substrates for beta-lactamase and uses thereof |
US7157575B2 (en) | 1995-03-20 | 2007-01-02 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
US6472205B1 (en) | 1995-03-20 | 2002-10-29 | The Regents Of The University Of California | Cytosolic forms for β-lactamase and uses thereof |
US6291162B1 (en) * | 1995-03-20 | 2001-09-18 | The Regents Of The University Of California | Cytosolic forms of beta-lactamase and uses thereof |
US5928888A (en) * | 1996-09-26 | 1999-07-27 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities |
US5955604A (en) * | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
US6339070B1 (en) | 1997-05-10 | 2002-01-15 | Zeneca Limited | Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
WO1999039741A2 (fr) | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Administration systemique de particules lipidiques du plasmide stables dans le serum en cancerotherapie |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
WO1999050406A3 (fr) * | 1998-04-01 | 1999-11-18 | Metamorphix Inc | Sequences regulatrices du facteur 9 de differenciation de croissance et utilisations associees |
WO1999050406A2 (fr) * | 1998-04-01 | 1999-10-07 | Metamorphix, Inc. | Sequences regulatrices du facteur 9 de differenciation de croissance et utilisations associees |
WO2000020608A1 (fr) * | 1998-10-02 | 2000-04-13 | Genotherapeutics, Inc. | Procede de traitement du cancer de la prostate au moyen d'un vecteur d'expression adenoviral codant pour une enzyme de promedicament |
US7227013B1 (en) | 1999-03-31 | 2007-06-05 | Metamorphix, Inc. | Growth differentiation factor-9 regulatory sequences and uses therefor |
WO2000066752A3 (fr) * | 1999-05-01 | 2001-04-05 | Astrazeneca Ab | Composes chimiques |
WO2000066752A2 (fr) * | 1999-05-01 | 2000-11-09 | Astrazeneca Ab | Composes chimiques |
US6838446B1 (en) | 1999-05-01 | 2005-01-04 | Astrazeneca Ab | Vector for expression of GPI-enzyme hybrid |
EP2118304A1 (fr) * | 2007-02-05 | 2009-11-18 | Panbio Limited | Dosages fec homogene in vitro et composants |
EP2118304A4 (fr) * | 2007-02-05 | 2010-04-28 | Panbio Ltd | Dosages fec homogene in vitro et composants |
JP2010517945A (ja) * | 2007-02-05 | 2010-05-27 | パンバイオ・リミテツド | 均一インビトロfecアッセイ及び成分 |
Also Published As
Publication number | Publication date |
---|---|
AU7700496A (en) | 1997-06-11 |
GB9523703D0 (en) | 1996-01-24 |
AU7583996A (en) | 1997-06-11 |
WO1997019183A2 (fr) | 1997-05-29 |
WO1997019180A3 (fr) | 1997-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2024253C (fr) | Entites pour le traitement du cancer | |
Marais et al. | Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination | |
US5837510A (en) | Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders | |
JP4272263B2 (ja) | 治療システム | |
WO1997019180A2 (fr) | Vecteur constitue d'une sequence d'adn de regulation de transcription liee a une sequence d'adn codant pour une beta-lactamase pour therapie a base d'un promedicament enzymatique | |
JP3747290B2 (ja) | 遺伝子指向性プロドラッグ療法における酵素の表面発現 | |
KR100361254B1 (ko) | 발현표적화를위한태아성암항원의전사조절서열 | |
AU7091196A (en) | Recombinant viruses incorporating a protease cleavable protein | |
JP2001522224A (ja) | 遺伝子治療における使用のための非免疫原性プロドラッグおよび選択マーカー | |
AU695375B2 (en) | Enzyme gene therapy catalysing prodrug extracellular conversion | |
Rigg et al. | Genetic prodrug activation therapy | |
JP4229982B2 (ja) | シトクロムp450を形質導入するレトロウイルスベクター | |
Abe et al. | Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector | |
Capiaux et al. | Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil | |
US20030228285A1 (en) | Bipartite T-cell factor (Tcf)-responsive promoter | |
NZ522753A (en) | Bacterial carboxypeptidase CPG2 variants and their use in gene directed enzyme prodrug therapy | |
WO1999060008A1 (fr) | Gene de cytosine deaminase | |
US20040166559A1 (en) | Vectors for gene therapy | |
US6130089A (en) | Materials and methods for gene transfer | |
US6537541B1 (en) | Implantation of HSV-TK retrovirus producer cells to destroy glioma | |
US6555108B1 (en) | Implanting HSV-TK retrovirus producing cells to treat tumors | |
AU663470B2 (en) | Viral particles having altered host range | |
Unger | Enriching suicide gene bearing tumor cells in vivo for an increased bystander effect: a novel strategy for cancer gene therapy | |
NZ751656A (en) | Improved thymidine kinase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG KE Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97519492 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |